The first human test of a rejuvenation method will begin “shortly”

A Boston startup, Life Biosciences, is set to conduct the first human trial of a rejuvenation method called "reprogramming" to treat eye disease. The technique involves resetting epigenetic controls in cells to restore a healthier state. The trial will involve injecting reprogramming genes into the eyes of patients with glaucoma, with the genes controlled by a genetic switch activated by an antibiotic. While the approach has shown promise in animals, there are concerns about potential risks, including cancer. The company's ultimate goal is to explore the potential for whole-body rejuvenation, but for now, the trial serves as a proof of concept for age reversal.